Volume 26, Issue 9 (12-2019)
RJMS 2019, 26(9): 29-38 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Moshfegh P, Aletaha M, Baradaran B. The effect of miR-34a replacement in the proliferation inhibition of cancerous cell line of esophagus. RJMS 2019; 26 (9) :29-38
URL: http://rjms.iums.ac.ir/article-1-5535-en.html
URL: http://rjms.iums.ac.ir/article-1-5535-en.html
Tabriz University of Medical Sciences, Tabriz, Iran , manal239@yahoo.com
Abstract: (3075 Views)
Background: Because of its malignancy and poor prognosis, esophageal cancer is the sixth cause of death around the world. MiR-34a is a tumor suppressor. The miRNA-34 family is involved in suppressing the tumor and oncogenic pathways in some cancers. The purpose of this research is to determine the changes in the expression of the Vimentin gene after the replacement of miR-34a, on the other hand the effect of replacing this micro-RNA on cell proliferation is determined.
Methods: After cultivating the TE-8 cell line, miR-34a was replaced in esophageal cancer cells and after miR-34a replacement, Vimentin gene expression was evaluated using qRT-PCR method. Cell proliferation in the TE-8 cell line was evaluated in effective time and dose after the replacement of mir-34a by the MTT method.
Results: Replacing miR-34a in the TE-8 cell line significantly reduced the expression of Vimentin (p<0.0001). Mir-34a could (at an effective dose) within 24 hours significantly reduce cell proliferation (p<0.0001).
Conclusion: Possibly, the replacement of miR-34a could have a therapeutic role in esophageal cancer.
Methods: After cultivating the TE-8 cell line, miR-34a was replaced in esophageal cancer cells and after miR-34a replacement, Vimentin gene expression was evaluated using qRT-PCR method. Cell proliferation in the TE-8 cell line was evaluated in effective time and dose after the replacement of mir-34a by the MTT method.
Results: Replacing miR-34a in the TE-8 cell line significantly reduced the expression of Vimentin (p<0.0001). Mir-34a could (at an effective dose) within 24 hours significantly reduce cell proliferation (p<0.0001).
Conclusion: Possibly, the replacement of miR-34a could have a therapeutic role in esophageal cancer.
Type of Study: Research |
Subject:
Hematology & oncology
References
1. 1. Radmard AR. Five common cancers in Iran. Arch Iran Med. 2010;13(2):143.
2. 2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
3. 3. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509(7498):91-5.
4. 4. Zhang R, Su B. Small but influential: the role of microRNAs on gene regulatory network and 3′ UTR evolution. JGG. 2009;36(1):1-6.
5. 5. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350.
6. 6. Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Bba-Mol Cell Res. 2010;1803(11):1231-43.
7. 7. Wang A-M, Huang T-T, Hsu K-W, Huang K-H, Fang W-L, Yang M-H, et al. Yin Yang 1 is a target of microRNA-34 family and contributes to gastric carcinogenesis. Oncotarget. 2014;5(13):5002.
8. 8. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17(2):193.
9. 9. Bader AG. miR-34–a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3.
10. 10. Tahergorabi Z, Moodi M, Mesbahzadeh B. Breast Cancer: A preventable disease. j birjand univ med sci. 2014;21(2):126-41.
11. 11. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501(7467):328-37.
12. 12. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108(3):479-85.
13. 13. Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, González-Fernández Á. Assessment of the Evolution of Cancer Treatment Therapies. Cancers (Basel). 2011;3(3): 3279–3330.
14. 14. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97.
15. 15. Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer lett. 2009;285(2):116-26.
16. 16. Ha M, Kim VN. Regulation of microRNA biogenesis. Nature reviews Molecular cell biology. 2014;15(8):509-24.
17. 17. Khoshmirsafa M, Seif F, Mohsenzadegan M, Najafi M, Mokhtarian K, Shekarabi M. Circulating microRNAs, valuable biomarkers in biological fluids. RJMS. 2017;24(160):22-36.
18. 18. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell cycle. 2008;7(6):759-64.
19. 19. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene. 2010;29(11):1580.
20. 20. Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res. 2008;68(1):26-33.
21. 21. McInroy L, Määttä A. Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem Biophys Res Commun. 2007;360(1):109-14.
22. 22. Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009;30(11):1903-9.
23. 23. Gao H, Zhao H, Xiang W. Expression level of human miR-34a correlates with glioma grade and prognosis. J Neurooncol. 2013;113(2):221-8.
24. 24. Jin K, Xiang Y, Tang J, Wu G, Li J, Xiao H, et al. miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells. Tumour Biol. 2014;35(2):1503-10.
25. 25. Zhang H, Li S, Yang J, Liu S, Gong X, Yu X. The prognostic value of miR-34a expression in completely resected gastric cancer: tumor recurrence and overall survival. Int J Clin Exp Med.
26. 2015;8(2):2635.
27. 26. Lin X, Xu X, Chen Q, Huang C. Clinical significance of microRNA-34a in esophageal squamous cell carcinoma. Genet Mol Res. 2015;14:17684-91.
28. 27. Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther. 2011;10(8):1470-80.
29. 28. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033-46.
30. 29. Ngan C, Yamamoto H, Seshimo I, Tsujino T, Man-i M, Ikeda J, et al. Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Br J Cancer. 2007;96(6):986-92.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
